Retatrutide vs Survodutide vs Mazdutide: A Research Comparison
The next generation of metabolic peptide research has moved beyond single-pathway GLP-1 biology into multi-receptor territory. Three compounds sit at the centre of that shift: Retatrutide, Survodutide, and Mazdutide. This comparison walks through how they relate — by receptor profile, mechanism, and research positioning — strictly within a research context.
The Core Difference: Two Receptors or Three
The single most important distinction between these three compounds is how many receptors each one engages.
- Retatrutide — a triple agonist. It activates three receptors: GLP-1, GIP, and glucagon (GCGR). It is the only triple agonist of the three.
- Survodutide — a dual agonist. It activates GLP-1 and glucagon.
- Mazdutide — a dual agonist. It activates GLP-1 and glucagon, and is structurally an oxyntomodulin analogue.
All three share the GLP-1 and glucagon arms. Retatrutide’s distinguishing feature is the added GIP receptor activity, which is the basis of much of the research interest in whether a third pathway meaningfully changes the metabolic picture.
The Shared Mechanism: GLP-1 and Glucagon
Because all three engage both GLP-1 and glucagon receptors, they share a common mechanistic core. The GLP-1 arm is associated with appetite suppression, slowed gastric emptying, and glucose-dependent insulin secretion. The glucagon (GCGR) arm is studied for its role in energy expenditure and hepatic fat oxidation. The research rationale that unites all three is the same: glucagon-driven energy expenditure may complement GLP-1-driven appetite reduction, potentially producing broader metabolic effects than a GLP-1 agonist alone.
What Sets Each One Apart
Retatrutide — the triple agonist
Retatrutide adds GIP receptor activity on top of the shared GLP-1/glucagon base. GIP is the same incretin receptor engaged by Tirzepatide, and its inclusion makes Retatrutide the most mechanistically complete of the three in terms of receptor coverage. For the full head-to-head with its dual-agonist predecessor, see Tirzepatide vs Retatrutide.
Survodutide — the liver-focused dual agonist
Survodutide shares the GLP-1/glucagon mechanism but is particularly associated in research with metabolic dysfunction-associated steatohepatitis (MASH) and hepatic lipid metabolism — the liver end of the metabolic field.
Mazdutide — the oxyntomodulin-analogue dual agonist
Mazdutide engages the same two receptors but is structurally derived from oxyntomodulin, a naturally occurring dual-receptor gut hormone. It is also noted for having the broadest Phase 3 research base of any GLP-1/glucagon dual agonist.
An Important Caveat on Comparison
It is worth being explicit: as of 2026, no published head-to-head trials exist between any pair of these three compounds. Every cross-compound comparison — including any percentage figures circulating online — is indirect, drawn from separate studies that used different populations, dose-escalation schedules, durations, and endpoints. Receptor count is a mechanistic fact; relative real-world effect is not something that can be read off cross-trial data. Any source that presents a confident “winner” between them is over-reaching what the published evidence supports.
Summary Table
- Retatrutide — GLP-1 + GIP + glucagon (triple). Developer: Eli Lilly. Distinguishing feature: only triple agonist; adds GIP.
- Survodutide — GLP-1 + glucagon (dual). Developer: Boehringer Ingelheim / Zealand. Distinguishing feature: liver/MASH research focus.
- Mazdutide — GLP-1 + glucagon (dual). Developer: Innovent / Eli Lilly. Distinguishing feature: oxyntomodulin analogue; large Phase 3 base.
Where These Sit in the Wider Landscape
These three are the glucagon-inclusive branch of next-generation metabolic research. A separate branch — combination therapies such as CagriSema — takes a different route entirely, adding the amylin pathway rather than glucagon. For the conceptual background on why the field moved toward multi-receptor designs, see our overview of triple agonists as the next frontier after dual agonists.
What to Look for When Sourcing
All three are long, acylated peptides that are complex to synthesise, making purity verification important. Look for an independent Certificate of Analysis confirming HPLC purity (≥98%) and mass spectrometry identity from a named third-party laboratory. Our guide on why COA testing matters explains what to check.
Compounds Referenced in This Article
This article is provided for educational purposes for laboratory research professionals. Retatrutide, survodutide, and mazdutide are investigational compounds and are not approved by the MHRA, FDA, or any equivalent regulatory body for the uses discussed. All Revial Labs compounds are supplied strictly for laboratory research use only and are not for human or veterinary use.
